Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting

Objectives: To determine the association of first, second, and third-line biologic disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib with drug survival among seropositive rheumatoid arthritis (RA) patients.Methods: The study population was composed of 8,018 seropositive RA patients who...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Choi, Seulggie [verfasserIn] Ghang, Byeongzu [verfasserIn] Jeong, Seogsong [verfasserIn] Choi, Daein [verfasserIn] Lee, Jeong Seok [verfasserIn] Park, Sang Min [verfasserIn] Lee, Eun Young [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	Biologic disease-modifying anti-rheumatic drugs Drug survival Rheumatoid arthritis

Übergeordnetes Werk:	Enthalten in: Seminars in arthritis and rheumatism - Philadelphia, Pa. : Saunders, 1971, 51, Seite 685-691
Übergeordnetes Werk:	volume:51 ; pages:685-691

DOI / URN:	10.1016/j.semarthrit.2021.06.002

Katalog-ID:	ELV006478883

Internformat


LEADER	01000caa a22002652 4500
001	ELV006478883
003	DE-627
005	20230524132348.0
007	cr uuu---uuuuu
008	230505s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.semarthrit.2021.06.002 \|2 doi
035			\|a (DE-627)ELV006478883
035			\|a (ELSEVIER)S0049-0172(21)00112-8
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
082	0	4	\|a 610 \|q DE-600
084			\|a 44.83 \|2 bkl
100	1		\|a Choi, Seulggie \|e verfasserin \|4 aut
245	1	0	\|a Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting
264		1	\|c 2021
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Objectives: To determine the association of first, second, and third-line biologic disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib with drug survival among seropositive rheumatoid arthritis (RA) patients.Methods: The study population was composed of 8,018 seropositive RA patients who were prescribed bDMARDs or tofacitinib between January 2014 and January 2019 from the Korean Health Insurance Review and Assessment Service database. First, second, and third-line choice of tumor necrosis factor inhibitors (TNFi) including etanercept, infliximab, adalimumab, and golimumab, as well as non-TNFi including tocilizumab, rituximab, tofacitinib, and abatacept were assessed. Multivariate Cox proportional hazards regression was used to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for drug failure according to bDMARD or tofacitinib choice starting from the initial prescription date.Results: Compared to first etanercept users, patients with first tocilizumab (aHR 0.56, 95% CI 0.46–0.68), tofacitinib (aHR 0.27, 95% CI 0.18–0.42), or abatacept (aHR 0.83, 95% CI 0.69–0.99) had lower risk of drug failure. Second choice of tocilizumab (aHR 0.38, 95% CI 0.25–0.55), tofacitinib (aHR 0.23, 95% CI 0.15–0.37), or abatacept (aHR 0.54, 95% CI 0.35–0.84) was associated with lower drug failure risk compared to second etanercept users. Finally, third choice of tocilizumab (aHR 0.32, 95% CI 0.16–0.62) or tofacitinib (aHR 0.35, 95% CI 0.19–0.63) was associated with lower drug failure risk compared to third TNFi users.Conclusion: First and second-line tocilizumab, tofacitinib, or abatacept may lead to improved drug survival. Third-line use of tocilizumab or tofacitinib may be beneficiary in reducing drug failure risk among seropositive RA patients.
650		4	\|a Biologic disease-modifying anti-rheumatic drugs
650		4	\|a Drug survival
650		4	\|a Rheumatoid arthritis
700	1		\|a Ghang, Byeongzu \|e verfasserin \|4 aut
700	1		\|a Jeong, Seogsong \|e verfasserin \|4 aut
700	1		\|a Choi, Daein \|e verfasserin \|4 aut
700	1		\|a Lee, Jeong Seok \|e verfasserin \|4 aut
700	1		\|a Park, Sang Min \|e verfasserin \|4 aut
700	1		\|a Lee, Eun Young \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Seminars in arthritis and rheumatism \|d Philadelphia, Pa. : Saunders, 1971 \|g 51, Seite 685-691 \|h Online-Ressource \|w (DE-627)330079441 \|w (DE-600)2048942-0 \|w (DE-576)097935018 \|x 1532-866X \|7 nnns
773	1	8	\|g volume:51 \|g pages:685-691
912			\|a GBV_USEFLAG_U
912			\|a SYSFLAG_U
912			\|a GBV_ELV
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_224
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4338
936	b	k	\|a 44.83 \|j Rheumatologie \|j Orthopädie
951			\|a AR
952			\|d 51 \|h 685-691

Indexfelder

author_variant	s c sc b g bg s j sj d c dc j s l js jsl s m p sm smp e y l ey eyl
matchkey_str	article:1532866X:2021----::soitoofrteodntidiedadadsmrwtdusriaaogeooiiehuaodrhii
hierarchy_sort_str	2021
bklnumber	44.83
publishDate	2021
allfields	10.1016/j.semarthrit.2021.06.002 doi (DE-627)ELV006478883 (ELSEVIER)S0049-0172(21)00112-8 DE-627 ger DE-627 rda eng 610 DE-600 44.83 bkl Choi, Seulggie verfasserin aut Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine the association of first, second, and third-line biologic disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib with drug survival among seropositive rheumatoid arthritis (RA) patients.Methods: The study population was composed of 8,018 seropositive RA patients who were prescribed bDMARDs or tofacitinib between January 2014 and January 2019 from the Korean Health Insurance Review and Assessment Service database. First, second, and third-line choice of tumor necrosis factor inhibitors (TNFi) including etanercept, infliximab, adalimumab, and golimumab, as well as non-TNFi including tocilizumab, rituximab, tofacitinib, and abatacept were assessed. Multivariate Cox proportional hazards regression was used to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for drug failure according to bDMARD or tofacitinib choice starting from the initial prescription date.Results: Compared to first etanercept users, patients with first tocilizumab (aHR 0.56, 95% CI 0.46–0.68), tofacitinib (aHR 0.27, 95% CI 0.18–0.42), or abatacept (aHR 0.83, 95% CI 0.69–0.99) had lower risk of drug failure. Second choice of tocilizumab (aHR 0.38, 95% CI 0.25–0.55), tofacitinib (aHR 0.23, 95% CI 0.15–0.37), or abatacept (aHR 0.54, 95% CI 0.35–0.84) was associated with lower drug failure risk compared to second etanercept users. Finally, third choice of tocilizumab (aHR 0.32, 95% CI 0.16–0.62) or tofacitinib (aHR 0.35, 95% CI 0.19–0.63) was associated with lower drug failure risk compared to third TNFi users.Conclusion: First and second-line tocilizumab, tofacitinib, or abatacept may lead to improved drug survival. Third-line use of tocilizumab or tofacitinib may be beneficiary in reducing drug failure risk among seropositive RA patients. Biologic disease-modifying anti-rheumatic drugs Drug survival Rheumatoid arthritis Ghang, Byeongzu verfasserin aut Jeong, Seogsong verfasserin aut Choi, Daein verfasserin aut Lee, Jeong Seok verfasserin aut Park, Sang Min verfasserin aut Lee, Eun Young verfasserin aut Enthalten in Seminars in arthritis and rheumatism Philadelphia, Pa. : Saunders, 1971 51, Seite 685-691 Online-Ressource (DE-627)330079441 (DE-600)2048942-0 (DE-576)097935018 1532-866X nnns volume:51 pages:685-691 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2143 GBV_ILN_2153 GBV_ILN_2336 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4313 GBV_ILN_4326 GBV_ILN_4334 GBV_ILN_4338 44.83 Rheumatologie Orthopädie AR 51 685-691
spelling	10.1016/j.semarthrit.2021.06.002 doi (DE-627)ELV006478883 (ELSEVIER)S0049-0172(21)00112-8 DE-627 ger DE-627 rda eng 610 DE-600 44.83 bkl Choi, Seulggie verfasserin aut Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine the association of first, second, and third-line biologic disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib with drug survival among seropositive rheumatoid arthritis (RA) patients.Methods: The study population was composed of 8,018 seropositive RA patients who were prescribed bDMARDs or tofacitinib between January 2014 and January 2019 from the Korean Health Insurance Review and Assessment Service database. First, second, and third-line choice of tumor necrosis factor inhibitors (TNFi) including etanercept, infliximab, adalimumab, and golimumab, as well as non-TNFi including tocilizumab, rituximab, tofacitinib, and abatacept were assessed. Multivariate Cox proportional hazards regression was used to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for drug failure according to bDMARD or tofacitinib choice starting from the initial prescription date.Results: Compared to first etanercept users, patients with first tocilizumab (aHR 0.56, 95% CI 0.46–0.68), tofacitinib (aHR 0.27, 95% CI 0.18–0.42), or abatacept (aHR 0.83, 95% CI 0.69–0.99) had lower risk of drug failure. Second choice of tocilizumab (aHR 0.38, 95% CI 0.25–0.55), tofacitinib (aHR 0.23, 95% CI 0.15–0.37), or abatacept (aHR 0.54, 95% CI 0.35–0.84) was associated with lower drug failure risk compared to second etanercept users. Finally, third choice of tocilizumab (aHR 0.32, 95% CI 0.16–0.62) or tofacitinib (aHR 0.35, 95% CI 0.19–0.63) was associated with lower drug failure risk compared to third TNFi users.Conclusion: First and second-line tocilizumab, tofacitinib, or abatacept may lead to improved drug survival. Third-line use of tocilizumab or tofacitinib may be beneficiary in reducing drug failure risk among seropositive RA patients. Biologic disease-modifying anti-rheumatic drugs Drug survival Rheumatoid arthritis Ghang, Byeongzu verfasserin aut Jeong, Seogsong verfasserin aut Choi, Daein verfasserin aut Lee, Jeong Seok verfasserin aut Park, Sang Min verfasserin aut Lee, Eun Young verfasserin aut Enthalten in Seminars in arthritis and rheumatism Philadelphia, Pa. : Saunders, 1971 51, Seite 685-691 Online-Ressource (DE-627)330079441 (DE-600)2048942-0 (DE-576)097935018 1532-866X nnns volume:51 pages:685-691 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2143 GBV_ILN_2153 GBV_ILN_2336 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4313 GBV_ILN_4326 GBV_ILN_4334 GBV_ILN_4338 44.83 Rheumatologie Orthopädie AR 51 685-691
allfields_unstemmed	10.1016/j.semarthrit.2021.06.002 doi (DE-627)ELV006478883 (ELSEVIER)S0049-0172(21)00112-8 DE-627 ger DE-627 rda eng 610 DE-600 44.83 bkl Choi, Seulggie verfasserin aut Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine the association of first, second, and third-line biologic disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib with drug survival among seropositive rheumatoid arthritis (RA) patients.Methods: The study population was composed of 8,018 seropositive RA patients who were prescribed bDMARDs or tofacitinib between January 2014 and January 2019 from the Korean Health Insurance Review and Assessment Service database. First, second, and third-line choice of tumor necrosis factor inhibitors (TNFi) including etanercept, infliximab, adalimumab, and golimumab, as well as non-TNFi including tocilizumab, rituximab, tofacitinib, and abatacept were assessed. Multivariate Cox proportional hazards regression was used to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for drug failure according to bDMARD or tofacitinib choice starting from the initial prescription date.Results: Compared to first etanercept users, patients with first tocilizumab (aHR 0.56, 95% CI 0.46–0.68), tofacitinib (aHR 0.27, 95% CI 0.18–0.42), or abatacept (aHR 0.83, 95% CI 0.69–0.99) had lower risk of drug failure. Second choice of tocilizumab (aHR 0.38, 95% CI 0.25–0.55), tofacitinib (aHR 0.23, 95% CI 0.15–0.37), or abatacept (aHR 0.54, 95% CI 0.35–0.84) was associated with lower drug failure risk compared to second etanercept users. Finally, third choice of tocilizumab (aHR 0.32, 95% CI 0.16–0.62) or tofacitinib (aHR 0.35, 95% CI 0.19–0.63) was associated with lower drug failure risk compared to third TNFi users.Conclusion: First and second-line tocilizumab, tofacitinib, or abatacept may lead to improved drug survival. Third-line use of tocilizumab or tofacitinib may be beneficiary in reducing drug failure risk among seropositive RA patients. Biologic disease-modifying anti-rheumatic drugs Drug survival Rheumatoid arthritis Ghang, Byeongzu verfasserin aut Jeong, Seogsong verfasserin aut Choi, Daein verfasserin aut Lee, Jeong Seok verfasserin aut Park, Sang Min verfasserin aut Lee, Eun Young verfasserin aut Enthalten in Seminars in arthritis and rheumatism Philadelphia, Pa. : Saunders, 1971 51, Seite 685-691 Online-Ressource (DE-627)330079441 (DE-600)2048942-0 (DE-576)097935018 1532-866X nnns volume:51 pages:685-691 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2143 GBV_ILN_2153 GBV_ILN_2336 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4313 GBV_ILN_4326 GBV_ILN_4334 GBV_ILN_4338 44.83 Rheumatologie Orthopädie AR 51 685-691
allfieldsGer	10.1016/j.semarthrit.2021.06.002 doi (DE-627)ELV006478883 (ELSEVIER)S0049-0172(21)00112-8 DE-627 ger DE-627 rda eng 610 DE-600 44.83 bkl Choi, Seulggie verfasserin aut Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine the association of first, second, and third-line biologic disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib with drug survival among seropositive rheumatoid arthritis (RA) patients.Methods: The study population was composed of 8,018 seropositive RA patients who were prescribed bDMARDs or tofacitinib between January 2014 and January 2019 from the Korean Health Insurance Review and Assessment Service database. First, second, and third-line choice of tumor necrosis factor inhibitors (TNFi) including etanercept, infliximab, adalimumab, and golimumab, as well as non-TNFi including tocilizumab, rituximab, tofacitinib, and abatacept were assessed. Multivariate Cox proportional hazards regression was used to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for drug failure according to bDMARD or tofacitinib choice starting from the initial prescription date.Results: Compared to first etanercept users, patients with first tocilizumab (aHR 0.56, 95% CI 0.46–0.68), tofacitinib (aHR 0.27, 95% CI 0.18–0.42), or abatacept (aHR 0.83, 95% CI 0.69–0.99) had lower risk of drug failure. Second choice of tocilizumab (aHR 0.38, 95% CI 0.25–0.55), tofacitinib (aHR 0.23, 95% CI 0.15–0.37), or abatacept (aHR 0.54, 95% CI 0.35–0.84) was associated with lower drug failure risk compared to second etanercept users. Finally, third choice of tocilizumab (aHR 0.32, 95% CI 0.16–0.62) or tofacitinib (aHR 0.35, 95% CI 0.19–0.63) was associated with lower drug failure risk compared to third TNFi users.Conclusion: First and second-line tocilizumab, tofacitinib, or abatacept may lead to improved drug survival. Third-line use of tocilizumab or tofacitinib may be beneficiary in reducing drug failure risk among seropositive RA patients. Biologic disease-modifying anti-rheumatic drugs Drug survival Rheumatoid arthritis Ghang, Byeongzu verfasserin aut Jeong, Seogsong verfasserin aut Choi, Daein verfasserin aut Lee, Jeong Seok verfasserin aut Park, Sang Min verfasserin aut Lee, Eun Young verfasserin aut Enthalten in Seminars in arthritis and rheumatism Philadelphia, Pa. : Saunders, 1971 51, Seite 685-691 Online-Ressource (DE-627)330079441 (DE-600)2048942-0 (DE-576)097935018 1532-866X nnns volume:51 pages:685-691 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2143 GBV_ILN_2153 GBV_ILN_2336 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4313 GBV_ILN_4326 GBV_ILN_4334 GBV_ILN_4338 44.83 Rheumatologie Orthopädie AR 51 685-691
allfieldsSound	10.1016/j.semarthrit.2021.06.002 doi (DE-627)ELV006478883 (ELSEVIER)S0049-0172(21)00112-8 DE-627 ger DE-627 rda eng 610 DE-600 44.83 bkl Choi, Seulggie verfasserin aut Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine the association of first, second, and third-line biologic disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib with drug survival among seropositive rheumatoid arthritis (RA) patients.Methods: The study population was composed of 8,018 seropositive RA patients who were prescribed bDMARDs or tofacitinib between January 2014 and January 2019 from the Korean Health Insurance Review and Assessment Service database. First, second, and third-line choice of tumor necrosis factor inhibitors (TNFi) including etanercept, infliximab, adalimumab, and golimumab, as well as non-TNFi including tocilizumab, rituximab, tofacitinib, and abatacept were assessed. Multivariate Cox proportional hazards regression was used to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for drug failure according to bDMARD or tofacitinib choice starting from the initial prescription date.Results: Compared to first etanercept users, patients with first tocilizumab (aHR 0.56, 95% CI 0.46–0.68), tofacitinib (aHR 0.27, 95% CI 0.18–0.42), or abatacept (aHR 0.83, 95% CI 0.69–0.99) had lower risk of drug failure. Second choice of tocilizumab (aHR 0.38, 95% CI 0.25–0.55), tofacitinib (aHR 0.23, 95% CI 0.15–0.37), or abatacept (aHR 0.54, 95% CI 0.35–0.84) was associated with lower drug failure risk compared to second etanercept users. Finally, third choice of tocilizumab (aHR 0.32, 95% CI 0.16–0.62) or tofacitinib (aHR 0.35, 95% CI 0.19–0.63) was associated with lower drug failure risk compared to third TNFi users.Conclusion: First and second-line tocilizumab, tofacitinib, or abatacept may lead to improved drug survival. Third-line use of tocilizumab or tofacitinib may be beneficiary in reducing drug failure risk among seropositive RA patients. Biologic disease-modifying anti-rheumatic drugs Drug survival Rheumatoid arthritis Ghang, Byeongzu verfasserin aut Jeong, Seogsong verfasserin aut Choi, Daein verfasserin aut Lee, Jeong Seok verfasserin aut Park, Sang Min verfasserin aut Lee, Eun Young verfasserin aut Enthalten in Seminars in arthritis and rheumatism Philadelphia, Pa. : Saunders, 1971 51, Seite 685-691 Online-Ressource (DE-627)330079441 (DE-600)2048942-0 (DE-576)097935018 1532-866X nnns volume:51 pages:685-691 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2143 GBV_ILN_2153 GBV_ILN_2336 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4313 GBV_ILN_4326 GBV_ILN_4334 GBV_ILN_4338 44.83 Rheumatologie Orthopädie AR 51 685-691
language	English
source	Enthalten in Seminars in arthritis and rheumatism 51, Seite 685-691 volume:51 pages:685-691
sourceStr	Enthalten in Seminars in arthritis and rheumatism 51, Seite 685-691 volume:51 pages:685-691
format_phy_str_mv	Article
bklname	Rheumatologie Orthopädie
institution	findex.gbv.de
topic_facet	Biologic disease-modifying anti-rheumatic drugs Drug survival Rheumatoid arthritis
dewey-raw	610
isfreeaccess_bool	false
container_title	Seminars in arthritis and rheumatism
authorswithroles_txt_mv	Choi, Seulggie @@aut@@ Ghang, Byeongzu @@aut@@ Jeong, Seogsong @@aut@@ Choi, Daein @@aut@@ Lee, Jeong Seok @@aut@@ Park, Sang Min @@aut@@ Lee, Eun Young @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	330079441
dewey-sort	3610
id	ELV006478883
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV006478883</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230524132348.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230505s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.semarthrit.2021.06.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV006478883</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0049-0172(21)00112-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Choi, Seulggie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives: To determine the association of first, second, and third-line biologic disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib with drug survival among seropositive rheumatoid arthritis (RA) patients.Methods: The study population was composed of 8,018 seropositive RA patients who were prescribed bDMARDs or tofacitinib between January 2014 and January 2019 from the Korean Health Insurance Review and Assessment Service database. First, second, and third-line choice of tumor necrosis factor inhibitors (TNFi) including etanercept, infliximab, adalimumab, and golimumab, as well as non-TNFi including tocilizumab, rituximab, tofacitinib, and abatacept were assessed. Multivariate Cox proportional hazards regression was used to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for drug failure according to bDMARD or tofacitinib choice starting from the initial prescription date.Results: Compared to first etanercept users, patients with first tocilizumab (aHR 0.56, 95% CI 0.46–0.68), tofacitinib (aHR 0.27, 95% CI 0.18–0.42), or abatacept (aHR 0.83, 95% CI 0.69–0.99) had lower risk of drug failure. Second choice of tocilizumab (aHR 0.38, 95% CI 0.25–0.55), tofacitinib (aHR 0.23, 95% CI 0.15–0.37), or abatacept (aHR 0.54, 95% CI 0.35–0.84) was associated with lower drug failure risk compared to second etanercept users. Finally, third choice of tocilizumab (aHR 0.32, 95% CI 0.16–0.62) or tofacitinib (aHR 0.35, 95% CI 0.19–0.63) was associated with lower drug failure risk compared to third TNFi users.Conclusion: First and second-line tocilizumab, tofacitinib, or abatacept may lead to improved drug survival. Third-line use of tocilizumab or tofacitinib may be beneficiary in reducing drug failure risk among seropositive RA patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biologic disease-modifying anti-rheumatic drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug survival</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rheumatoid arthritis</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ghang, Byeongzu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jeong, Seogsong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Choi, Daein</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Jeong Seok</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Park, Sang Min</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Eun Young</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Seminars in arthritis and rheumatism</subfield><subfield code="d">Philadelphia, Pa. : Saunders, 1971</subfield><subfield code="g">51, Seite 685-691</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)330079441</subfield><subfield code="w">(DE-600)2048942-0</subfield><subfield code="w">(DE-576)097935018</subfield><subfield code="x">1532-866X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:51</subfield><subfield code="g">pages:685-691</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="j">Rheumatologie</subfield><subfield code="j">Orthopädie</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">51</subfield><subfield code="h">685-691</subfield></datafield></record></collection>
author	Choi, Seulggie
spellingShingle	Choi, Seulggie ddc 610 bkl 44.83 misc Biologic disease-modifying anti-rheumatic drugs misc Drug survival misc Rheumatoid arthritis Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting
authorStr	Choi, Seulggie
ppnlink_with_tag_str_mv	@@773@@(DE-627)330079441
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
issn	1532-866X
topic_title	610 DE-600 44.83 bkl Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting Biologic disease-modifying anti-rheumatic drugs Drug survival Rheumatoid arthritis
topic	ddc 610 bkl 44.83 misc Biologic disease-modifying anti-rheumatic drugs misc Drug survival misc Rheumatoid arthritis
topic_unstemmed	ddc 610 bkl 44.83 misc Biologic disease-modifying anti-rheumatic drugs misc Drug survival misc Rheumatoid arthritis
topic_browse	ddc 610 bkl 44.83 misc Biologic disease-modifying anti-rheumatic drugs misc Drug survival misc Rheumatoid arthritis
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Seminars in arthritis and rheumatism
hierarchy_parent_id	330079441
dewey-tens	610 - Medicine & health
hierarchy_top_title	Seminars in arthritis and rheumatism
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)330079441 (DE-600)2048942-0 (DE-576)097935018
title	Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting
ctrlnum	(DE-627)ELV006478883 (ELSEVIER)S0049-0172(21)00112-8
title_full	Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting
author_sort	Choi, Seulggie
journal	Seminars in arthritis and rheumatism
journalStr	Seminars in arthritis and rheumatism
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2021
contenttype_str_mv	zzz
container_start_page	685
author_browse	Choi, Seulggie Ghang, Byeongzu Jeong, Seogsong Choi, Daein Lee, Jeong Seok Park, Sang Min Lee, Eun Young
container_volume	51
class	610 DE-600 44.83 bkl
format_se	Elektronische Aufsätze
author-letter	Choi, Seulggie
doi_str_mv	10.1016/j.semarthrit.2021.06.002
dewey-full	610
author2-role	verfasserin
title_sort	association of first, second, and third-line bdmards and tsdmard with drug survival among seropositive rheumatoid arthritis patients: cohort study in a real world setting
title_auth	Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting
abstract	Objectives: To determine the association of first, second, and third-line biologic disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib with drug survival among seropositive rheumatoid arthritis (RA) patients.Methods: The study population was composed of 8,018 seropositive RA patients who were prescribed bDMARDs or tofacitinib between January 2014 and January 2019 from the Korean Health Insurance Review and Assessment Service database. First, second, and third-line choice of tumor necrosis factor inhibitors (TNFi) including etanercept, infliximab, adalimumab, and golimumab, as well as non-TNFi including tocilizumab, rituximab, tofacitinib, and abatacept were assessed. Multivariate Cox proportional hazards regression was used to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for drug failure according to bDMARD or tofacitinib choice starting from the initial prescription date.Results: Compared to first etanercept users, patients with first tocilizumab (aHR 0.56, 95% CI 0.46–0.68), tofacitinib (aHR 0.27, 95% CI 0.18–0.42), or abatacept (aHR 0.83, 95% CI 0.69–0.99) had lower risk of drug failure. Second choice of tocilizumab (aHR 0.38, 95% CI 0.25–0.55), tofacitinib (aHR 0.23, 95% CI 0.15–0.37), or abatacept (aHR 0.54, 95% CI 0.35–0.84) was associated with lower drug failure risk compared to second etanercept users. Finally, third choice of tocilizumab (aHR 0.32, 95% CI 0.16–0.62) or tofacitinib (aHR 0.35, 95% CI 0.19–0.63) was associated with lower drug failure risk compared to third TNFi users.Conclusion: First and second-line tocilizumab, tofacitinib, or abatacept may lead to improved drug survival. Third-line use of tocilizumab or tofacitinib may be beneficiary in reducing drug failure risk among seropositive RA patients.
abstractGer	Objectives: To determine the association of first, second, and third-line biologic disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib with drug survival among seropositive rheumatoid arthritis (RA) patients.Methods: The study population was composed of 8,018 seropositive RA patients who were prescribed bDMARDs or tofacitinib between January 2014 and January 2019 from the Korean Health Insurance Review and Assessment Service database. First, second, and third-line choice of tumor necrosis factor inhibitors (TNFi) including etanercept, infliximab, adalimumab, and golimumab, as well as non-TNFi including tocilizumab, rituximab, tofacitinib, and abatacept were assessed. Multivariate Cox proportional hazards regression was used to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for drug failure according to bDMARD or tofacitinib choice starting from the initial prescription date.Results: Compared to first etanercept users, patients with first tocilizumab (aHR 0.56, 95% CI 0.46–0.68), tofacitinib (aHR 0.27, 95% CI 0.18–0.42), or abatacept (aHR 0.83, 95% CI 0.69–0.99) had lower risk of drug failure. Second choice of tocilizumab (aHR 0.38, 95% CI 0.25–0.55), tofacitinib (aHR 0.23, 95% CI 0.15–0.37), or abatacept (aHR 0.54, 95% CI 0.35–0.84) was associated with lower drug failure risk compared to second etanercept users. Finally, third choice of tocilizumab (aHR 0.32, 95% CI 0.16–0.62) or tofacitinib (aHR 0.35, 95% CI 0.19–0.63) was associated with lower drug failure risk compared to third TNFi users.Conclusion: First and second-line tocilizumab, tofacitinib, or abatacept may lead to improved drug survival. Third-line use of tocilizumab or tofacitinib may be beneficiary in reducing drug failure risk among seropositive RA patients.
abstract_unstemmed	Objectives: To determine the association of first, second, and third-line biologic disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib with drug survival among seropositive rheumatoid arthritis (RA) patients.Methods: The study population was composed of 8,018 seropositive RA patients who were prescribed bDMARDs or tofacitinib between January 2014 and January 2019 from the Korean Health Insurance Review and Assessment Service database. First, second, and third-line choice of tumor necrosis factor inhibitors (TNFi) including etanercept, infliximab, adalimumab, and golimumab, as well as non-TNFi including tocilizumab, rituximab, tofacitinib, and abatacept were assessed. Multivariate Cox proportional hazards regression was used to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for drug failure according to bDMARD or tofacitinib choice starting from the initial prescription date.Results: Compared to first etanercept users, patients with first tocilizumab (aHR 0.56, 95% CI 0.46–0.68), tofacitinib (aHR 0.27, 95% CI 0.18–0.42), or abatacept (aHR 0.83, 95% CI 0.69–0.99) had lower risk of drug failure. Second choice of tocilizumab (aHR 0.38, 95% CI 0.25–0.55), tofacitinib (aHR 0.23, 95% CI 0.15–0.37), or abatacept (aHR 0.54, 95% CI 0.35–0.84) was associated with lower drug failure risk compared to second etanercept users. Finally, third choice of tocilizumab (aHR 0.32, 95% CI 0.16–0.62) or tofacitinib (aHR 0.35, 95% CI 0.19–0.63) was associated with lower drug failure risk compared to third TNFi users.Conclusion: First and second-line tocilizumab, tofacitinib, or abatacept may lead to improved drug survival. Third-line use of tocilizumab or tofacitinib may be beneficiary in reducing drug failure risk among seropositive RA patients.
collection_details	GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2143 GBV_ILN_2153 GBV_ILN_2336 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4313 GBV_ILN_4326 GBV_ILN_4334 GBV_ILN_4338
title_short	Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting
remote_bool	true
author2	Ghang, Byeongzu Jeong, Seogsong Choi, Daein Lee, Jeong Seok Park, Sang Min Lee, Eun Young
author2Str	Ghang, Byeongzu Jeong, Seogsong Choi, Daein Lee, Jeong Seok Park, Sang Min Lee, Eun Young
ppnlink	330079441
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1016/j.semarthrit.2021.06.002
up_date	2024-07-06T21:30:59.925Z
_version_	1803866823643365376
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV006478883</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230524132348.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230505s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.semarthrit.2021.06.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV006478883</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0049-0172(21)00112-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Choi, Seulggie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives: To determine the association of first, second, and third-line biologic disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib with drug survival among seropositive rheumatoid arthritis (RA) patients.Methods: The study population was composed of 8,018 seropositive RA patients who were prescribed bDMARDs or tofacitinib between January 2014 and January 2019 from the Korean Health Insurance Review and Assessment Service database. First, second, and third-line choice of tumor necrosis factor inhibitors (TNFi) including etanercept, infliximab, adalimumab, and golimumab, as well as non-TNFi including tocilizumab, rituximab, tofacitinib, and abatacept were assessed. Multivariate Cox proportional hazards regression was used to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for drug failure according to bDMARD or tofacitinib choice starting from the initial prescription date.Results: Compared to first etanercept users, patients with first tocilizumab (aHR 0.56, 95% CI 0.46–0.68), tofacitinib (aHR 0.27, 95% CI 0.18–0.42), or abatacept (aHR 0.83, 95% CI 0.69–0.99) had lower risk of drug failure. Second choice of tocilizumab (aHR 0.38, 95% CI 0.25–0.55), tofacitinib (aHR 0.23, 95% CI 0.15–0.37), or abatacept (aHR 0.54, 95% CI 0.35–0.84) was associated with lower drug failure risk compared to second etanercept users. Finally, third choice of tocilizumab (aHR 0.32, 95% CI 0.16–0.62) or tofacitinib (aHR 0.35, 95% CI 0.19–0.63) was associated with lower drug failure risk compared to third TNFi users.Conclusion: First and second-line tocilizumab, tofacitinib, or abatacept may lead to improved drug survival. Third-line use of tocilizumab or tofacitinib may be beneficiary in reducing drug failure risk among seropositive RA patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biologic disease-modifying anti-rheumatic drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug survival</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rheumatoid arthritis</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ghang, Byeongzu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jeong, Seogsong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Choi, Daein</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Jeong Seok</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Park, Sang Min</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Eun Young</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Seminars in arthritis and rheumatism</subfield><subfield code="d">Philadelphia, Pa. : Saunders, 1971</subfield><subfield code="g">51, Seite 685-691</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)330079441</subfield><subfield code="w">(DE-600)2048942-0</subfield><subfield code="w">(DE-576)097935018</subfield><subfield code="x">1532-866X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:51</subfield><subfield code="g">pages:685-691</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="j">Rheumatologie</subfield><subfield code="j">Orthopädie</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">51</subfield><subfield code="h">685-691</subfield></datafield></record></collection>
score	7.4010477

Nicht das Richtige dabei?

Schreiben Sie uns!

Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?